

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN ISSUER  
Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For the month of July 2005

Commission File Number 000-51122

**pSivida Limited**  
(Translation of registrant's name into English)

Level 12 BGC Centre  
28 The Esplanade  
Perth WA 6000  
(Address of principal executive offices)

(Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F).

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- \_\_\_\_.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant, pSivida Limited, has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

pSivida Limited

Date: July 25, 2005

By: /s/ Aaron Finlay  
Aaron Finlay  
Chief Financial Officer and Company Secretary

---

EXHIBIT INDEX

EXHIBIT 99.1: pSivida appoints CEO of Chugai Pharma USA as a Non-Executive Director.  
Business Development Focus

---

**pSivida appoints CEO of Chugai Pharma USA as a Non-Executive Director.**

**Business Development Focus**

Global nanotechnology company pSivida Limited (**ASX:PSD, NASDAQ:PSDV, Xetra:PSI**) is pleased to announce the appointment of Dr. David J. Mazzo as a Non-executive Director of the company, based in New Jersey, USA.

As President and CEO of Chugai Pharma USA, Dr. Mazzo brings his significant business development experience and pharmaceutical network to the Board. His appointment follows pSivida's recent NASDAQ listing and will further assist pSivida's strategy to increase its visibility in the US pharmaceutical and capital markets.

Chugai Pharma USA is part of the Roche group of companies and is a subsidiary of Chugai Pharmaceutical Company Limited (Japan), a global research-based pharmaceutical company with sales in 2001 of US\$1.7 billion.

Dr. Mazzo is recognized for his strong scientific and regulatory expertise with broad technical and managerial experience gained from working in a variety of multi-cultural and multi-lingual environments in the USA, Europe and Asia.

Dr. Mazzo holds a Bachelor of Arts with Honors (Interdisciplinary Humanities) and a B.S. with Honors in Chemistry from Villanova University, as well as a Master of Science in Chemistry and a Ph.D in Analytical Chemistry from the University of Massachusetts. He complemented his American education as a Research Fellow at the École Polytechnique Fédérale de Lausanne, Switzerland.

pSivida's Managing Director Mr Gavin Rezos said, "We are very fortunate to have David join the Board. David brings a unique and powerful blend of scientific and business skills that will greatly assist pSivida's expansion in the US market."

Dr. Mazzo has published often and is frequently invited to present at international pharmaceutical conferences. He served as a member of the Nasal Drug Products subcommittee of the FDA Advisory Committee for Pharmaceutical Science and presently serves as an advisor to a number of academic and investment organisations.

The pSivida Board engaged Tamara P. Davis, Managing Director, Corporate Governance Practice at Levin & Company, Inc. Boston., Massachusetts, to assist in this important Board Director recruitment.

**-ENDS-**

**Released by:**

**pSivida Limited**  
Brian Leedman  
Investor Relations  
pSivida Limited  
Tel: + 61 8 9327 5099  
brianl@psivida.com

**US Public Relations**  
Beverley Jedynek  
President  
Martin E. Janis & Company, Inc  
Tel: +1 (312) 9 1100 ext. 12  
bjedynek@janispr.com

**UK & Europe Public Relations**  
Mark Swallow, PhD / Helena Podd  
Citigate Dewe Rogerson  
Tel: +44 (0)20 7282 2948 / 2867  
mark.swallow@citigatedr.co.uk

## NOTES TO EDITORS:

### **pSivida Limited**

pSivida is a global nanotechnology company committed to the biomedical sector and the development of products in healthcare. The company's focus is the development and commercialisation of a modified form of silicon (porosified or nano-structured silicon) known as BioSilicon™. As a new and exciting biocompatible material, BioSilicon™ offers multiple potential applications across the high growth healthcare sector, including controlled release drug delivery, targeted cancer therapies (including brachytherapy and localized chemotherapy), tissue engineering and orthopedics. Potential diagnostics applications are being developed through its subsidiary AION Diagnostics Limited.

pSivida owns the intellectual property rights to BioSilicon™ for use in or on humans and animals. The IP portfolio consists of 26 patent families, 29 granted patents and over 80 patent applications. The core patent, which recognises BioSilicon™ as a biomaterial was granted in the UK in 2000 and in the US in 2001.

pSivida is listed on NASDAQ (**PSDV**), the Australian Stock Exchange (**PSD**) and in Germany on the Frankfurt Stock Exchange on the XETRA system (**German Symbol: PSI. Securities Code (WKN) 358705**). pSivida's shares also trade in the United Kingdom on the OFEX International Market Service (IMS) under the ticker symbol **PSD**.

The Company's strategic partner and largest shareholder is the QinetiQ group, the largest science and technology company in Europe. QinetiQ is the former UK government Defence Evaluation Research Agency and was instrumental in discovering BioSilicon™. pSivida enjoys a strong relationship with QinetiQ having access to its cutting edge research and development facilities. For more information on QinetiQ visit [www.qinetiq.com](http://www.qinetiq.com).

For more information visit [www.psivida.com](http://www.psivida.com)

This document contains forward-looking statements that involve risks and uncertainties. Although we believe that the expectations reflected in such forward-looking statements are reasonable at this time, we can give no assurance that such expectations will prove to be correct. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Actual results could differ materially from those anticipated in these forward-looking statements due to many important factors including: our failure to develop applications for BioSilicon™ due to regulatory, scientific or other issues. Other reasons are contained in cautionary statements in the Registration Statement on Form 20-F filed with the U.S. Securities and Exchange Commission, including, without limitation, under Item 3.D, "Risk Factors" therein. We do not undertake to update any oral or written forward-looking statements that may be made by or on behalf of pSivida.

---

